Page 5 - Daniel Teper News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cytovia Therapeutics Files New Patents for its Natural Killer Cell Engager Multifunctional Antibodies (FLEX-NK®) for the Treatment of Hematological and Solid Tumors First-in-class NK Engager multifunctional antibody products can activate patients’ own NK cells or be combined with Cytovia’s off-the-shelf Universal iPSC-derived NK Cells April 12, 2021 11:11 ET | Source: Cytovia Therapeutics Cytovia Therapeutics Miami, Florida, UNITED STATES CAMBRIDGE, Mass. and AVENTURA, Fla., April 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutic...

  Australia is home to 733 active fintech companies, up from 629 in September 2019, reveals KPMG’s Fintech Landscape 2020 map. This represents an increase of 104 companies that joined the sector between September 2019 and December 2020. The infographic, released on December 21, 2020, provides a snapshot of the Australian fintech ecosystem, revealing several major trends that have emerged over the past year. In particular, the blockchain and cryptocurrency segment saw the strongest growth with 49 new companies being established. It’s followed by lending with the addition to 26 companies (...

Shares of Immune Pharmaceuticals Inc (NASDAQ: IMNP) were trending last week, gaining as much as 76 percent in three days. With no material news surfacing, it seemed like the rally was driven by a recent article that featured the company. Shares have given up most of the gains on Thursday trading.... Read More... Don't Miss Any Updates! News Directly in Your Inbox Subscribe to:

Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells Cellectis Inc.; Cytovia Therapeutics, Inc. New York, New York, UNITED STATES CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical compan...

(MENAFN - GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic 'off-the-shelf' gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that they have entered into a strategic research and development collab...